Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
            <i>Enterobacterales</i>
            Strains, Including Carbapenem-Resistant Isolates

Shortridge, Dee; Kantro, Valerie; Castanheira, Mariana

doi:10.1128/spectrum.04507-22

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier studies in the Arabian Gulf Peninsula have consistently shown the predominance of the OXA-48 family among CRE, which support the current findings shown in Figure 1 [40][41][42]. This is in contrast to the USA, where another serine-carbapenemase "KPC" has been described as the most frequent genotype in K. pneumoniae [43][44][45].…”

Section: Discussionsupporting

confidence: 90%

Predictive role of culture-based MIC testing vs. genotyping for carbapenem-resistant Enterobacterales in a non-universal screening, highly resourced setting

Alnimr

2023

ELECTRON J GEN MED

View full text Add to dashboard Cite

A lack of evidence of accuracy for various testing modalities for carbapenem-resistant Enterobacterales (CRE) reduces the efficiency of screening and delays the isolation of carriers. This study examined the performance of phenotypic detection of CRE in comparison to molecular testing. A cross-sectional study was conducted in an academic medical institution in Saudi Arabia on CRE-screened patients during a 36-month period (April 1, 2019, through March 31, 2022). Cases were followed up for their susceptibility status by the phenotypic gradient method and genotypes. Of 3,116 samples tested, 359 carbapenemase genes were detected in 297 strains (9.5%) belonging to 292 patients. Oxacilliniase-48 (OXA-48) was the most frequently detected genotype (n=190, 64%), followed by a combined New Delhi metallo-B-lactamase (NDM)/OXA-48 genotype (n=77, 25.9%). Variable missed isolation days were encountered for various genotypes (0-18.5 days), with an excellent clinical utility index obtained for screening the OXA-48 genotype phenotypically. The data provided some insights into the predictive role and shortcomings of the e-test alone in CRE screening. While it provided a reasonable approach in a CRE population dominated by OXA-48 genotypes, it was more likely to miss the NDM-incurred carbapenemase. Thus, local epidemiology in an institution must be considered when designing a local screening protocol in addition to consideration of cost and turnaround time.

show abstract

Section: Discussionsupporting

confidence: 90%

Predictive role of culture-based MIC testing vs. genotyping for carbapenem-resistant Enterobacterales in a non-universal screening, highly resourced setting

Alnimr

2023

ELECTRON J GEN MED

View full text Add to dashboard Cite

show abstract

Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms

Koenig,

Kuti

2024

Pharmacotherapy

View full text Add to dashboard Cite

Antibiotic resistance has become a global threat as it is continuously growing due to the evolution of β‐lactamases diminishing the activity of classic β‐lactam (BL) antibiotics. Recent antibiotic discovery and development efforts have led to the availability of β‐lactamase inhibitors (BLIs) with activity against extended‐spectrum β‐lactamases as well as Klebsiella pneumoniae carbapenemase (KPC)‐producing carbapenem‐resistant organisms (CRO). Nevertheless, there is still a lack of drugs that target metallo‐β‐lactamases (MBL), which hydrolyze carbapenems efficiently, and oxacillinases (OXA) often present in carbapenem‐resistant Acinetobacter baumannii. This review aims to provide a snapshot of microbiology, pharmacology, and clinical data for currently available BL/BLI treatment options as well as agents in late stage development for CRO harboring various β‐lactamases including MBL and OXA‐enzymes.

show abstract

Reviewing novel treatment options for carbapenem-resistant Enterobacterales

Mackow,

van Duin

2024

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates

Cited by 4 publications

References 25 publications

Predictive role of culture-based MIC testing vs. genotyping for carbapenem-resistant Enterobacterales in a non-universal screening, highly resourced setting

Predictive role of culture-based MIC testing vs. genotyping for carbapenem-resistant Enterobacterales in a non-universal screening, highly resourced setting

Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms

Reviewing novel treatment options for carbapenem-resistant Enterobacterales

Contact Info

Product

Resources

About